UNSPSC 51281649: Gentamicin a

This classification denotes an aminoglycoside antibiotic with the molecular formula C18H36N4O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4W8R3URS2H, chemically known as d-streptamine, o-2-amino-2-deoxy-.alpha.-d-glucopyranosyl-(1->4)-o-(3-deoxy-3-(methylamino)-.alpha.-d-xylopyranosyl-(1->6))-2-deoxy-, but more generally known as gentamicin a, which bears US NIH Compound Identifier 86474.

European Medicines Agency schedules gentamicin a or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02326MIG. Most nations, for tariff purposes, schedule gentamicin a under HS 29419000. SMILES: CN[C@H]1[C@H](CO[C@@H]([C@@H]1O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)N)N)N)O.

UNSPSC 51281649 Gentamicin a is a Commodity code under which state and local governments procure pharmaceutical products, though recent opportunities show the code being applied to a broader range of medical and pharmaceutical supplies and programs beyond the specific gentamicin antibiotic the code nominally describes. State and local issuing bodies soliciting under this code—including county health departments, municipal fire departments, state health agencies, and cooperative purchasing consortia—are acquiring emergency medical supplies, over-the-counter pharmaceutical products, generic multi-source pharmaceuticals, and prescription fulfillment services through a mix of competitive sealed bids, RFPs, and requests for information that gather vendor capabilities before formal procurement.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Representative solicitations include Seminole County, Florida's IFB for naloxone and safe drug deactivation systems (1,900 units of naloxone and 800 deactivation systems annually, due Jul 26, 2023); the City of Tampa Fire Department's IFB for 169 line items of medical and first aid supplies including respiratory equipment, cardiac monitoring electrodes, and oxygen delivery systems, with an estimated contract value of $700,000.00 and a Small Local Business Enterprise set-aside with a 5% bid discount not to exceed $10,000 (due Mar 13, 2026); Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon, requiring vendor pricing through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) with proposals due Mar 26, 2026; and Texas Health and Human Services Commission's RFI regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program exploring direct contracting between state pharmacy benefit programs and manufacturers outside traditional PBM and GPO arrangements (response due Apr 3, 2026).